Endpoint Selection in Rare Disease Trials: Composite Measures and the Loss of Interpretability. Translational Medicine & Therapeutics Journal, [S. l.], v. 5, n. 2, p. 10–18, 2026. DOI: 10.5281/zenodo.22649538. Disponível em: https://inkwise.org/index.php/TMTJ/article/view/117. Acesso em: 5 nov. 2026.